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ASSESSMENT OF CHLOROQUINE SINGLE DOSE TREATMENT OF MALARIA DUE TO
Plasmodium vivax IN BRAZILIAN AMAZON
Ana Yecê das Neves PINTO(1), Carolina Heitmann AZEVEDO(2), Janaína Bezerra da SILVA(2) & José Maria de SOUZA(1)
SUMMARY
Malaria regions of the Amazon basin have been characterized by difficult access and non-compliance of the patients to treatment.
In an attempt to assess the schizonticide efficacy of chloroquine in a single dose of 600 mg, the authors realized a double-blind,
placebo-controlled trial in 132 outpatients with vivax malaria. Patients were distributed into two groups: group CPLA, given chloroquine
600 mg (single dose) on the first day of treatment, and two doses of placebo on second and third days. Group CHLO, given chloroquine
600 mg on first day and 450 mg on second and third day. Geometric means of the parasite density during the follow-up was similar
in both groups. No differences were observed in the parasitological cure between the two groups (p = 0.442). There was clinical and
parasitological efficacy in treatment of patients given a single-dose of chloroquine. This suggests that its restricted use could be
indicated in remote areas of Brazilian Amazon Region, nevertheless the inadequate response of three patients indicates the need for
further studies.
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INTRODUCTION
There is a continuous search for new antimalarial drugs or new
therapeutic methods that reinforce the acceptance of the drugs by the
patients with malaria. The long duration and faster clinical recovery
obtained in the first forty-eight hours of treatment influence significantly
the decision to abandon treatment. Many authors have been investigating
whether a decrease in the doses of antimalarial drugs or shorter treatment
period could be as effective as those used in the standards schemes5,22,23,24.
In the Malaria Program of the Evandro Chagas Institute the
observation that treatment was often abandoned on day 2 or 3, has
motivated studies to establish regimens with the goal of decreasing the
duration of treatment and consequently increasing the patients acceptance
of the doses1,16. The results of those studies demonstrated that lower
doses of chloroquine and primaquine led to clinical and parasitological
cure, as well as the standard scheme, and such modified schemes could
be indicated in certain areas of the Amazon Region.
Following those encouraging results the authors decided to extend
the studies to test chloroquine at a dosage decreased to 10 mg/kg and
determine whether the chloroquine still acts as an effective schizonticide
up to the end of day 3 of treatment and compare the results with traditional
scheme (three doses) of antimalarial treatment with the same drug.
METHODS
Area: The study was conducted in the municipal district of Belém,
located in the Northeast of Pará State. Estimated population is 1,144,312
inhabitants, of whom 65% are living in the city outskirts. In 1999, 3,630
malaria cases were registered in the municipal district, with an infection
rate <5%, and thus is considered to be an area of low transmission.
Procedures: A clinical, double-blind, placebo-controlled trial was
performed. One hundred and thirty-two patients were included from
January 1997 to August 1998 with inclusion criteria: age over 11 years;
presenting a single infection by P. vivax with ≥ 500 parasites/mm3 in
thick blood smears; without recent history of antimalarial drug use
(preceding thirty days); no severe vomiting or diarrhea, or other factors
that might decrease absorption of the drugs; consent to participate;
permanence in Belém city throughout the study period. Informed consent
was obtained from the patients. Pregnant and breast-feeding women were
excluded.
In an attempt to assess the asexual parasitemia, blood was collected
from patients by finger puncture and a thick blood smear was stained by
Giemsa method. The number of parasites, per 200 white blood cells
(WBCs) was estimated at a magnification of 1,000X. This procedure
was carried out on days D0 (first day of treatment), D1, D2, D3, D4 and
on D5 (even if the thick films were negative) and again on D7, D14,
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D21 and D28, in agreement with recommendations of assessment studies
on antimalarial drugs efficacy by World Health Organization (WHO)3,14.
Treatment and follow-up: The patients were randomly assigned to
receive one of the therapeutic regimens in two treatment groups:
chloroquine/placebo (CPLA) given 600 mg of chloroquine on the day 1
and 450 mg of placebo tablets on days 2 and 3, associated with 15 mg of
primaquine daily for 14 days; chloroquine/chloroquine (CHLO) given
600 mg of chloroquine on the day 1, 450 mg of chloroquine on days 2
and 3, associated with 15 mg of primaquine daily for 14 days. Each
tablet of chloroquine used in the study was prepared by a manipulation
pharmacy in the form of a tablet, in order to obtain a homogeneous
presentation of the drug.
The responses to treatment were classified by a new system, which
differs from the traditional one in degrees, due to its concentration on
surveillance during a short period (surveillance concentrated on days 0,
3, 7 and 14). Instead, we used an adaptation of the times and extending
the study up to days 22 and 2914.
The following situations were considered:
Response A. Parasite density on D3 is above 25% compared with
D0, or if this patient needed alternative antimalarial treatment on D3.
Response B. Thick blood smear positive on D3, with a parasite density
down to 25%, compared with the parasite density on D0, and which
becomes positive (recrudescence of asexual parasitemia) on D7, or if
this patient needs alternative antimalarial treatment on any day between
D3 and D7.
Response C. Other situations that included patients with a positive
thick blood smear but with a parasite density less than 25% compared
with that of D0 and which later (until D28) became negative. This
response corresponds to response type “LFT– I” (Late Failure of the
Treatment).
Parasitological cure. Disappearance of asexual parasitemia by day
5 of treatment in two negative serial thick films, without evidence of
recrudescence up until day 28 after beginning treatment. This corresponds
to response type “ACR” (Appropriate Clinical Response).
The patients who presented relapses were treated with 600 mg of
chloroquine on the first day and 450 mg on the second and third days,
associated with 15 mg/kg/day primaquine for 14 days.
Statistical analysis: At the end of the study, the randomization code
was broken and the data were included in the microcomputer database
program: EPI INFO, version 6.04.
Parasitological evidence of cure was calculated by the proportion of
patients with negative thick blood films on days: D4, D5, D7 and D14,
compared to the total of patients included in each treatment group.
Patients who could not be followed up were considered as “treatment
failure” in order to avoid distortions of comparison (intention to treat)18.
The geometric mean parasite density (GMPD) was calculated taking
to account the parasitemia level of the patients (evidence of clearance),
excluding those considered resistant by the previous time-period
evaluation. The GMPD was assessed on days D0, D1, D2, D3, D7 and
D14, and compared in both groups. Fisher’s exact test was used
to compare proportions of patients that had cure response to the
treatment, p values (two-sided) less than 0.05 were considered
significant.
RESULTS
One hundred and forty patients were enrolled in the study. Eight
patients were excluded due to lack of follow-up or due to errors in the
treatment. Thus a total of one hundred and thirty two patients were
studied. After treatment codes breaking, sixty-five used treatment CHLO
and sixty-seven used treatment CPLA.
Baseline data for the 132 subjects and their initial asexual parasitemia
in each group are shown in Table 1.
Fever was present in 76.3% of the patients before treatment. In those
patients treated with scheme CHLO, 91.2% were fever free on the fourth
day of treatment, while, in the same period, 88.1% of those treated with
scheme CPLA were without fever (Table 2).
During the weekly follow up, headache was a frequent symptom,
and was present for more than seven days in some cases. In both groups
there were reports of headache up to day 15 after beginning treatment.
Among the patients of the group CPLA, only 49.2% (29/59) had no
headache up to day 4 of treatment.
The GMPD during and after treatment is shown in Figure 1. All
patients showed clearance of parasitemia up to day 5 of treatment. Two
patients from group CHLO and one from group CPLA presented
precocious recrudescence of asexual parasitemia on the day 22 after
Table 1
Characteristics of treatment groups CHLO (standard dose) and CPLA (reduced dose)
Characteristics Treatment groups
CHLO n = 65 CPLA n = 67
Female (%) 23 (35.4%) 27 (40.3)
Male (%) 42 (64.6%) 40 (59.7)
Mean age (SD)* 29.5 (±11.7) 31.9 (± 16.0)
Mean weight (Kg) 59 47.5
GMDP † at day 0 (amplitude) 1,9907/mm3 (500 - 14,000) 2,3128/mm3 (500 - 20,000)
* SD = Standard deviation; † GMPD = Geometric means of parasite density at D0
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initiation of treatment. They were treated again, as indicated in Methods,
and showed good response to the second treatment.
Parasitological response to treatment is shown in Table 3. Comparison
of responses type A, B and C in both groups did not reveal a statistically
significant difference significance (p = 0.442).
Table 2
Disappearance of signs and symptoms of malaria (fever, chills and migraine) during the week of treatment in two studied groups
Signs or symptoms D1 D2 D3 Cumulative partial (%) D4 D5 D7 Cumulative
Fever CHLO 20 24 8 52 (91.2) - 1 - 53 (92.0)
CPLA 23 25 4 52 (88.1) - - 4 56 (95.0)
Chills CHLO 25 20 4 49 (86.0) 1 1 3 54 (94.7)
CPLA 18 30 2 50 (94.3) - - 2 52 (99.0)
Migraine CHLO 9 23 10 42 (65.6) 1 1 6 50 (78.1)
CPLA 10 15 4 29 (49.2) 3 1 10 43 (72.9)
Table 3
Therapeutic response obtained in the follow-up of patients in two
studied groups
Therapeutic response  Group CHLO Group CPLA
Parasitological cure 47 56
Response “A” 0 0
Response “B” 0 0
Response “C” 2 1
Indefinite* 16 10
TOTAL 65 67
Fisher’s Exact Test: p = 0.442; * Follow-up to D21 (incomplete)
Fig. 1 - Geometric means of parasite density in groups CHLO and CPLA, on days 0 (beginning of treatment) to day 4 and also on days 7, 14, 21 and on day 28 after beginning of treatment.
Regarding side effects of the drugs, patients from group CHLO had
more pruritus, paresthesia, diarrhea, nausea and vomiting then those from
group CPLA. Sweat, visual hallucinations, cyanoses and dyspnea were
present in one patient from group CPLA.
DISCUSSION
The abandonment of treatment by patients with vivax malaria has
been frequently reported. Consequently, the search for more useful
schemes must be incessant, in an attempt to determine the probable impact
upon relapses on the control programs, as a result of noncompliance.
We consider that the most useful schemes of treatment are those
with a short duration or those using a small quantity of drugs. An example
is the use of primaquine, the only drug that has an action against
hypnozoite forms of Plasmodium vivax. Up to 1996, primaquine had
been used in Brazil at 0.25 mg/kg/day over 14 days. However, in view
of the prolonged treatment, this dose has been changed to a recommended
dose of 0.50 mg/kg/day over a shorter period of seven days8.
In the State of Pará, a serious situation of vivax malaria has prompted
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the Malaria Control Programs in Brazil to seek for more feasible schemes
of treatment, in view of the difficulties that prolonged treatment imposes17.
The present work has shown the effectiveness of a scheme using a single
dose of chloroquine, comparable to the classical schemes. Similar results
have been obtained in Asia and Africa6,7.
During the eradication campaigns in Brazil, during 1958, a so-called
“presumptive dose” of chloroquine was established. This consisted of a
single dose of four tablets (150 mg base or 600 mg) of chloroquine given
to the residents with fever in areas of difficult access and diagnosis. In
these areas, the results of thick blood film would be available only three
days after the collection of blood. Thus, improvement of symptoms and
immediate prevention of transmission were ensured by the “presumptive
dose” while patients waited for the result of their tests. Those patients
with positive results received subsequent doses of primaquine13. There
was evidence of a complete clearance of asexual parasitemia in those
patients given the single dose of four tablets, and the effectiveness of
chloroquine against P. vivax was obtained as a result of a whole-blood
chloroquine concentration of approximately 90 µg/mL. This concentration
was almost always surpassed during the classic treatment with 25 mg/kg
of chloroquine. The possibility of using reduced doses of chloroquine for
the treatment of vivax malaria4,11,12 was emphasized.
Obviously, the first question following the decrease of antimalarial
doses, is if they could induce parasite resistance. P. vivax resistance to
chloroquine has been reported since 1989 in New Papua Guinea,
Indonesia, in addition to other areas of the Asian continent19,20,21. In Brazil,
there are two reports of probable chloroquine-resistance to P. vivax. One
occurred in the State of Amazonas, where it was reported in one person
with an anomalous and unique parasite response to two antimalarial
drugs: chloroquine and mefloquine2. The other report occurred in the
state of Rondônia, though this was possibly due to a relapse following
inadequate treatment with primaquine9,10.
Theoretically, antimalarial compounds with a short half-life reduce
the selectivity pressure for resistance25. Chloroquine is one of the
antimalarial drugs with the longest half-life that we know. This could be
the cause of fast development of resistance by P. falciparum to this drug
and some recent evidence of decreased response of P. vivax to
chloroquine.
The early recrudescence of asexual parasitemia (day 21) in three
patients who curiously were asymptomatic or oligosymptomatic,
occurred in both those using chloroquine for three days and those
administered chloroquine in a single dose. This suggests an inadequate
response to chloroquine that should be better studied. It is possible that
carriers of vivax malaria from the Amazon region have an inadequate
response to chloroquine and that this could pass undiagnosed since the
standard cure controls recommended by the Fundação Nacional de Saúde
[National Health Foundation] are only performed 30, 60, 90, 120, 150
and 180 days after the treatment. There is a possibility that, within a
mean period of 20 days after beginning treatment, the patients present a
limited parasitological recrudescence per si, without a manifest clinical
picture. This phenomenon has been demonstrated by DANIEL &
MOLTA (1989). They used a single dose of chloroquine in the treatment
of 53 children, in which the failure of schizonticide action of chloroquine
was demonstrated and this was not associated with clinical disease7.
Three patients showing recrudescence during the follow-up, two of
them had taken chloroquine for three days, suggesting that inadequate
response is independent of chloroquine dose usually given.
Side effects occurred in both groups, but were much more evident in
the group CHLO. The most frequent signs and symptoms were nausea
and vomiting, diarrhea, pruritus, paresthesia and abdominal pain. Some
of these signs and symptoms cannot be distinguished from those produced
by primaquine. Pruritus and paresthesia, invariably produced by
chloroquine15, were more evident in the patients from group CHLO.
We have demonstrated that a scheme using a single dose of
chloroquine in the treatment of vivax malaria is as effective as the standard
scheme. So, it could therefore be used in areas of difficult access in
Brazilian Amazon, in an attempt to increase patient’s acceptance of
treatment and to resolve the problem of abandoned treatment. However,
the possibility of inadequate response of P. vivax to this drug, shown by
some other authors and suggested in the present work, indicates the need
for further studies to evaluate the real impact that reduced doses of
chloroquine would have in antimalarial treatment in Brazil.
RESUMO
Cloroquina em dose simples no tratamento da malária por
Plasmodium vivax na Amazônia brasileira
As regiões malarígenas da Amazônia brasileira têm se caracterizado
por dificuldades no acesso ao tratamento e não aceitação das drogas
pelos doentes. Com objetivos de avaliar a eficácia da cloroquina em
dose simples de 600 mg, os autores realizaram um ensaio clínico duplo
cego, placebo controlado em 132 pacientes portadores de malária por P.
vivax. Os pacientes foram distribuídos em dois grupos: grupo CPLA
que recebia 600 mg de cloroquina em dose simples no primeiro dia de
tratamento e duas doses de placebo no segundo e terceiro dias de
tratamento. Grupo CLO que recebia 600 mg de cloroquina no primeiro
dia e 450 mg no segundo e terceiro dias. A média geométrica da densidade
parasitária durante o seguimento foi similar em ambos os grupos. Não
houve diferenças de cura parasitológica em ambos os grupos (p = 0,442).
Observou-se eficácia clínica e parasitológica nos indivíduos que
receberam dose simples de cloroquina, indicando a possibilidade de uso
restrito a algumas áreas da Amazônia brasileira, contudo, a resposta
inadequada de três pacientes sugere a necessidade de outros estudos.
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